Elevate System
Phase 1- Indications
- High-risk coronary intervention, Cardiogenic shock
Company intelligence / Profile preview
Magenta Medical is developing Elevate™, a miniaturized percutaneous Left Ventricular Assist Device (pLVAD) designed to provide temporary mechanical circulatory support for patients with acute heart dysfunction. The Elevate™ system has completed a U.S. Early Feasibility Study for high-risk PCI and is preparing for a pivotal randomized controlled trial in the U.S., targeting both HR-PCI and cardiogenic shock indications. The technology has received FDA Breakthrough Device Designation for these uses.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Magenta Medical.